Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: A systematic review

Liver Transplantation

Volumn 16, Issue 3, 2010, Pages 300-307

  Saab, Sammy ^a   Waterman, Benjamin ^a   Chi, Amanda C ^a   Tong, Myron J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; LAMIVUDINE;

CLINICAL TRIAL; DRUG EFFICACY; FOLLOW UP; GRAFT RECIPIENT; HEPATITIS B; HUMAN; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; INFECTION RISK; LIVER TRANSPLANTATION; META ANALYSIS; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULINS; LAMIVUDINE; LIVER TRANSPLANTATION;

EID: 77749323292     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21998     Document Type: Review

References (34)

1. Health Resources and Services Administration. Organ Procurement and Transplantation Network. http://optn.transplant.hrsa.gov. Accessed November 2009.
2. Saab S, Chang AJ, Comulada S, Geevarghese SK, Anselmo RD, Durazo F, et al. Outcomes of hepatitis C-and hepatitis B core antibody-positive grafts in orthotopic liver transplantation. Liver Transpl 2003;9: 1053-1061.
3. Munoz SJ. Use of hepatitis B core antibody-positive donors for liver transplantation. Liver Transpl 2002;8: S82-S87.
4. McQuillan GM, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999;89:14-18.
5. Prieto M, Gomez MD, Berenguer M, Cordoba J, Rayon JM, Pastor M, et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-Hbc positivity in the donor population. Liver Transpl 2001;7:1-58.
6. Manzarbeitia C, Reich D, Ortiz J, Rosthstein K, Araya V, Munoz S. Safe use of liver donors with positive hepatitis B core antibody. Liver Transpl 2002;8:556-561.
7. Douglas DD, Rakela J, Wright TL, Krom RA, Wiesner RH. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surgery 1997;3:105-111.
8. Chazouillères O, Mamish D, Kim M, Carey K, Ferrell L, Roberts JP, et al. "Occult" hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994;343: 142-146.
9. Wachs ME, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 1995;59:230-234.
10. Dickson RC, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997;113:1668-1674.
11. Uemoto S, Sugiyama K, Marusawa H, Inomata Y, Asonuma K, Egawa H, et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 1998;65: 494-499.
12. Donataccio D, Roggen F, De Reyck C, Verbaandert C, Bodeus M, Lerut J. Use of anti-HBc positive allografts in adult liver transplantation: toward a safer way to expand the donor pool. Transpl Int 2006;19:38-43.
13. Barcena R, Moraleda G, Moreno J, Martín MD, de Vicente E, Nuño J, et al. Prevention of de novo HBV infection by the presence of anti-HBs in transplanted patients receiving core antibody-positive livers. World J Gastroenterol 2006;12:2070-2074.
14. Perrillo R. Hepatitis B virus prevention strategies for antibody to hepatitis B core antigen-positive liver donation: a survey of North American, European, and Asian-Pacific transplant. Liver Transpl 2009;15:223-232.
15. Nery JR, Nery-Avila C, Reddy KR, Cirocco R, Weppler D, Levi DM, et al. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation 2003;75:1179-1186.
16. Dodson SF, Bonham CA, Geller DA, Cacciarelli TV, Rakela J, Fung JJ. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999;68:1058-1061.
17. Holt D, Thomas R, Van Thiel D, Brems JJ. Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation. Arch Surg 2002;137:572-575.
18. Fábrega E, García-Suarez C, Guerra A, Orive A, Casafont F, Crespo J, Pons-Romero F. Liver transplantation with allografts from hepatitis B core antibody-positive donors: a new approach. Liver Transpl 2003;9:916-920.
19. Jain A, Orloff M, Abt P, Kashyap R, Mohanka R, Lansing K, et al. Use of hepatitis B core antibody-positive liver allograft in hepatitis C virus-positive and -negative recipients with use of short course of hepatitis B immunoglobulin and Lamivudine. Transplant Proc 2005;37: 3187-3189.
20. Loss GE Jr, Mason AL, Nair S, Blazek J, Farr G, Guo L, et al. Does lamivudine prophylaxis eradicate persistent HBV DNA from allografts derived from anti-HBc-positive donors? Liver Transpl 2003;9:1258-1264.
21. Suehiro T, Shimada M, Kishikawa K, Shimura T, Soejima Y, Yoshizumi T, et al. Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation. Liver Int 2005;25: 1169-1174.
22. Celebi Kobak A, Karasu Z, Kilic M, Ozacar T, Tekin F, Gunsar F, et al. Living donor liver transplantation from hepatitis B core antibody positive donors. Transplant Proc 2007;39:1488-1490.
23. Chen YS, Wang CC, de Villa VH, Wang SH, Cheng YF, Huang TL, et al. Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors. Clin Transplant 2002;16:405-409.
24. Ikegami T, Taketomi A, Ohta R, Soejima Y, Yoshizumi T, Harada N, et al. The risks of HBV infection after liver transplantation from HBc antibody positive donor to HBs antibody positive recipient. Hepatogastroenterology 2008; 55:2162-2165.
25. Prakoso E, Strasser SI, Koorey DJ, Verran D, McCaughan GW. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors. Clin Transplant 2006;20:369-373.
26. Yu AS, Vierling JM, Colquhoun SD, Arnaout WS, Chan CK, Khanafshar E, et al. Transmission of hepatitis B infection from hepatitis B core antibody - positive liver allografts is prevented by lamivudine therapy. Liver Transpl 2001;7:513-517.
27. Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007; 39:397-408.
28. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006;131:59-68.
29. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study. Gastroenterology 1991;100:182-188.
30. YeoW, Chan TC, Leung NW, LamWY, Mo FK, ChuMT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009;27:605-611.
31. Saab S, Ham MY, Stone MA, Holt C, Tong M. Decision analysis model for hepatitis B prophylaxis one year after liver transplantation. Liver Transpl 2009;15:413-420.
32. PDR Staff. Red Book. 113th ed. Montvale, NJ: Thomson Healthcare; 2009.
33. de Villa VH, Chen YS, Chen CL. Hepatitis B core antibody-positive grafts: recipient's risk. Transplantation 2003;75(suppl):S49-S53.
34. Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology 2009;49(suppl):S174-S184.